Profilo
Andrea Grant served as the Chief Executive Officer, Executive Director & MD at Algorae Pharmaceuticals Ltd.
from 2012 to 2014.
Prior to that, she was the Chief Executive Officer at Diatranz Otsuka Ltd.
and the Managing Director at Galapagos Genomics NV.
Dr. Grant received her undergraduate and doctorate degrees from the University of Cambridge.
Precedenti posizioni note di Andrea Grant
Società | Posizione | Fine |
---|---|---|
ALGORAE PHARMACEUTICALS LIMITED | Amministratore Delegato | 01/04/2014 |
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Corporate Officer/Principal | 02/05/2008 |
Diatranz Otsuka Ltd.
Diatranz Otsuka Ltd. Pharmaceuticals: MajorHealth Technology Diatranz Otsuka Ltd. manufactures pharmaceutical products. Its product, DIABECELL, is used to treat type1 diabetes. The company was founded on November 11, 2011 and is headquartered in Auckland, New Zealand. | Amministratore Delegato | - |
Formazione di Andrea Grant
University of Cambridge | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
ALGORAE PHARMACEUTICALS LIMITED | Health Technology |
Aziende private | 2 |
---|---|
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Health Technology |
Diatranz Otsuka Ltd.
Diatranz Otsuka Ltd. Pharmaceuticals: MajorHealth Technology Diatranz Otsuka Ltd. manufactures pharmaceutical products. Its product, DIABECELL, is used to treat type1 diabetes. The company was founded on November 11, 2011 and is headquartered in Auckland, New Zealand. | Health Technology |
- Borsa valori
- Insiders
- Andrea Grant